Upstream Bio (UPB) Stock Price, News & Analysis

Company Overview

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages. In the immuno-oncology sphere, Upstream Bio is exploring therapeutic vaccine constructs designed to activate tumor-specific T cells, while its infectious disease programs seek to induce protective immunity against viral pathogens. By integrating translational biomarkers and adaptive clinical trial designs, the company strives to accelerate candidate selection and optimize dosing regimens.

Upstream Bio operates research facilities in the United States and collaborates with academic and industry partners across several regions to advance its programs globally. The company’s leadership team comprises seasoned executives and scientists with deep expertise in virology, vaccine development and regulatory affairs. Upstream Bio is listed on the Nasdaq Global Market under the symbol UPB and continues to build strategic alliances aimed at expanding its pipeline and commercial capabilities.

Key Stats

• Today's Range: $6.46 to $7.11
• 50-Day Range: $5.92 to $7.98
• 52-Week Range: $5.85 to $33.68
• Volume: 147,401 shs
• Average Volume: 864,875 shs
• Market Capitalization: $369.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.67
• Consensus Rating: Hold

Upstream Bio Stock Analysis - MarketRank™

Upstream Bio scored higher than 30% of companies evaluated by MarketBeat, and ranked 758th out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Upstream Bio has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Upstream Bio has a consensus price target of $29.67, representing about 349.8% upside from its current price of $6.60.

Amount of Analyst Coverage

Upstream Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Upstream Bio are expected to decrease in the coming year, from ($2.86) to ($2.93) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Upstream Bio is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Upstream Bio is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Upstream Bio has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.03% of the float of Upstream Bio has been sold short.

Short Interest Ratio / Days to Cover

Upstream Bio has a short interest ratio ("days to cover") of 7.49.

Change versus previous month

Short interest in Upstream Bio has recently increased by 0.84%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Upstream Bio does not currently pay a dividend.

Dividend Growth

Upstream Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for UPB on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Upstream Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.46% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Upstream Bio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 8/24/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:UPB
• Previous Symbol: NASDAQ:UPB
• CIK: 2022626
• Web: upstreambio.com
• Phone: (781) 208-2466
• Fax: N/A
• Employees: 38
• Year Founded: 2021

Price Target and Rating

• Average Price Target for Upstream Bio: $29.67
• High Price Target: $50.00
• Low Price Target: $9.00
• Potential Upside/Downside: +339.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$143.44 million
• Net Margins: -4,955.67%
• Pretax Margin: -4,955.67%
• Return on Equity: -48.40%
• Return on Assets: -46.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.99
• Quick Ratio: 27.99

Sales & Book Value

• Annual Sales: $2.85 million
• Price / Sales: 129.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.29 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 54,770,000
• Free Float: 45,756,000
• Market Cap: $369.75 million
• Optionable: N/A
• Beta: 1.26